SINGAPORE: At the height of her eczema flare, Ms Chloe Ng struggled to hold a pen or carry a spoon as her fingers were covered in open wounds. For years, she cycled through treatments, including oral ...

Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...

New long-term data show Eli Lilly and Company's Ebglyss (lebrikizumab-lbkz) delivered durable skin clearance?and?relief from persistent?itch for up to four years for patients with moderate-to-severe ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) presented interim data from the ADlong Phase 3b study showing its atopic dermatitis treatment Ebglyss maintained skin clearance and itch relief for up ...

In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high bar of near-complete skin ...

Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, Regeneron and Sanofi, prompting analysts to double their peak sales forecast to ...

While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...